L-Arginine
|
Basic information |
| Metabolite name | L-Arginine |
 | HMDB0000517 |
 |
C00062 |
 |
6322 |
| Synonyms | Arg; |
| No. of studies | 46 |
|
Basic information |
| Metabolite name | L-Arginine |
| HMDB0000517 |
|
C00062 |
|
6322 |
| Synonyms | Arg; |
| No. of studies | 46 |
|
Relationship between L-Arginine and depression (count: 46) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M065 | Type2 | depressed group at 6-weeks treatment vs. baseline | Plasma | Human | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M085 | Type3 | ketamine group vs. control group at 24 h after treatment | Serum | Cynomolgus monkey | Up |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1023 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Down |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1032 | Type2 | CUMS + Bupleurum chinense DC and Paeonia lactiflora Pall group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1032 | Type2 | CUMS + Paeonia lactiflora Pall group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1032 | Type2 | CUMS + Bupleurum chinense DC group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M1056 | Type2 | maternal separation + beraprost group vs. maternal separation group | Serum | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Down |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M1076 | Type2 | depression group, post Shuganjieyu treatment vs. baseline | Plasma | Human | Down |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M1097 | Type2 | probiotic-treated depression group vs. placebo-treated depression group | Faece | Human | Up |
| Study M132 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M456 | Type1 | depressed group vs. control group | Serum | Human | Down |
| Study M464 | Type1 | drug-naive MDD group vs. control group | Plasma | Human | Up |
| Study M464 | Type1 | drug-treatment MDD group vs. control group | Plasma | Human | Up |
| Study M472 | Type3 | (2S,6S)-HNK group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | S-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M472 | Type3 | R-Ket group vs. control group | PC12 cell | Rat | Up |
| Study M539 | Type2 | LPS+ Dl-3-n-butylphthalide group vs. LPS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M543 | Type1 | summer depression group vs. summer control group | Plasma | Human | Up |
| Study M562 | Type2 | high fat diet + DSM32386 group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M592 | Type1 | CUMS group vs. control group, LC-MS | Liver | Sprague-Dawley rat | Down |
| Study M592 | Type2 | CUMS + high dose of XYS group vs. CUMS group, LC-MS | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M593 | Type2 | CUMS + high dose of Radix Bupleuri-Radix Paeoniae Alba herb pair group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M593 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M617 | Type2 | CUMS + ellagic acid group vs. CUMS group | Serum | C57BL/6 mouse | Down |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M639 | Type1 | MDD group vs. control group | Plasma | Human | Up |
| Study M691 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M741 | Type2 | MDD group, post vs. before SSRI treatment | Plasma | Human | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M846 | Type2 | postpartum depression model + 919 syrup group vs. postpartum depression model group | Hippocampus | BALB/c mouse | Down |
| Study M882 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M896 | Type1 | eating disorders with MDD group vs. eating disorders without MDD group | Plasma | Human | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M912 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |